Torcetrapib
CAS: 262352-17-0
Rif. 3D-FT15754
| 5mg | Prezzo su richiesta | ||
| 10mg | Prezzo su richiesta | ||
| 25mg | Prezzo su richiesta |
Informazioni sul prodotto
- (2R,4S)-4-[(3,5-Bis-trifluoromethylbenzyl)methoxycarbonylamino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester
- (2R,4S)-4-[[3,5-Bis(trifluoromethyl)benzyl]methoxycarbonylamino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester
- 1(2H)-Quinolinecarboxylic acid, 4-[[[3,5-bis(trifluoromethyl)phenyl]methyl](methoxycarbonyl)amino]-2-ethyl-3,4-dihydro-6-(trifluoromethyl)-, ethyl ester, (2R,4S)-
- Cp 529414
- ethyl (2R,4S)-4-{[3,5-bis(trifluoromethyl)benzyl](methoxycarbonyl)amino}-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate
Torcetrapib is a drug that inhibits the enzyme DPP-IV, which is responsible for the degradation of a protein called DPP-4. Torcetrapib has been shown to improve atherosclerotic lesions in humans and mice by inhibiting DPP-IV, which prevents the destruction of DPP-4. It also increases levels of a protein called IL-2 receptor, which is involved in immune response and inhibition of tumour growth. Torcetrapib has not been shown to be carcinogenic or mutagenic in animal models. Torcetrapib binds to the cytosolic Ca2+ channel and reduces the activity of this channel, inhibiting cellular proliferation and reducing cholesterol levels in cells. Torcetrapib also has low potency against proteins such as IL-2 receptor and cytosolic Ca2+.
Proprietà chimiche
Richiesta tecnica su: 3D-FT15754 Torcetrapib
Se si desidera richiedere un preventivo o effettuare un ordine, si prega invece di aggiungere i prodotti desiderati al carrello e poi richiedere un preventivo o un ordine dal carrello. È più veloce, più economico, e potrà beneficiare degli sconti disponibili e di altri vantaggi.
